Retinal vein occlusion
The PBS subsidises ranibizumab and aflibercept for patients with visual impairment due to macular oedema secondary to retinal vein occlusion.
Treatment with ranibizumab and aflibercept can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with visual impairment due to macular oedema secondary to retinal vein occlusion.
Ranibizumab and aflibercept are also used for patients with visual impairment due to macular oedema secondary to:
- branched retinal vein occlusion (BRVO), or
- central retinal vein occlusion (CRVO)
Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing ranibizumab and aflibercept.
Emergency treatments only
Apply for initial approval over the phone to avoid delays in starting treatment. You must fax the completed application form and authority prescription form to the PBS Complex Drugs Programs enquiry line. We'll contact the prescriber by phone. You must then send the original application form and a copy of the optical coherence tomography or fluorescein angiography to the PBS Complex Drugs Programs address.
Authority approval for initial treatment of each eye is required. Make all initial applications for authority approval to prescribe ranibizumab and aflibercept for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion for each eye in writing and:
- upload through Health Professional Online Services, or
- post to the PBS Complex Drugs Programs address
All applications must include a completed:
- authority prescription form, and
- Retinal Vein Occlusion Initial PBS authority application Supporting information form (PB154)
For more information call the PBS Complex Drugs Programs enquiry line.